Jump to content

PD-1 and PD-L1 inhibitors

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Auvideo (talk | contribs) at 15:02, 28 September 2019 (→Experimental: Fixed typo which lead to confusing different types of cancers). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Micrograph showing a PD-L1 positive lung adenocarcinoma. Positive immunostaining can predict response to the treatment.

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.[1]

PD-1 and PD-L1 inhibitors act to inhibit the association of the programmed death-ligand 1 (PD-L1) with its receptor, programmed cell death protein 1 (PD-1). The interaction of these cell surface proteins is involved in the suppression of the immune system and occurs following infection to limit the killing of bystander host cells and prevent autoimmune disease.[2] This immune checkpoint is also active in pregnancy,[3] following tissue allografts,[4] and in different types of cancer.[5]

Approved PD-1/PD-L1 inhibitors
Name Target Approved
Nivolumab PD-1 2014
Pembrolizumab PD-1 2014
Atezolizumab PD-L1 2016
Avelumab PD-L1 2017
Durvalumab PD-L1 2017
Cemiplimab PD-1 2018

History

The concept of blocking PD-1 and PD-L1 for the treatment of cancer was first published in 2001.[6] Pharmaceutical companies began attempting to develop drugs to block these molecules, and the first clinical trial was launched in 2006, evaluating nivolumab. As of 2017, more than 500 clinical trials involving PD-1 and PD-L1 inhibitors have been conducted in more than 20,000 patients.[7] By the end of 2017, PD-1/PD-L1 inhibitors had been approved for the treatment of nine forms of cancer.[8]

Cancer immunotherapy

In the cancer disease state, the interaction of PD-L1 on the tumor cells with PD-1 on a T-cell reduces T-cell function signals to prevent the immune system from attacking the tumor cells.[9] Use of an inhibitor that blocks the interaction of PD-L1 with the PD-1 receptor can prevent the cancer from evading the immune system in this way.[9] Several PD-1 and PD-L1 inhibitors are being trialled within the clinic for use in advanced melanoma, non-small cell lung cancer, renal cell carcinoma, bladder cancer and Hodgkin lymphoma, amongst other cancer types.[5]

Immunotherapy with these immune checkpoint inhibitors appears to shrink tumours in a higher number of patients across a wider range of tumour types and is associated with lower toxicity levels than other immunotherapies, with durable responses.[5] However, de-novo and acquired resistance is still seen in a large proportion of patients.[9] Hence PD-L1 inhibitors are considered to be the most promising drug category for many different cancers.[5][10]

Not all patients respond to PD-1/PD-L1 inhibitors. The FDA has approved several assays to measure the level of PD-L1 expressed by tumor cells, in order to predict the likelihood of response to an inhibitor. PD-L1 levels have been found to be highly predictive of response. Higher mutation burden is also predictive of response to anti-PD-1/PD-L1 agents.[8]

PD-1 and PD-L1 inhibitors are closely related to CTLA4 (cytotoxic T-lymphocyte-associated protein 4) inhibitors, such as ipilimumab. PD-1 and CTLA-4 are both expressed on activated T cells, but at different phases of immune response.[7]

Current clinical trials are evaluating anti-PD-1 and PD-L1 drugs in combination with other immunotherapy drugs blocking LAG3, B7-H3, KIR, OX40, PARP, CD27, and ICOS.[7]

Therapeutics

PD-1

Pembrolizumab (formerly MK-3475 or lambrolizumab, Keytruda) was developed by Merck and first approved by the Food and Drug Administration in 2014 for the treatment of melanoma. It was later approved for metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. In 2017, it became the first immunotherapy drug approved for use based on the genetic mutations of the tumor rather than the site of the tumor. It was shown, that patients with higher non-synonymous mutation burden in their tumors respond better to the treatment. Both their objective response rate and progression-free survival was shown to be higher than in patients with low non-synonymous mutation burden.[11]

Nivolumab (Opdivo) was developed by Bristol-Myers Squibb and first approved by the FDA in 2014 for the treatment of melanoma. It was later approved for squamous cell lung cancer, renal cell carcinoma, and Hodgkin's lymphoma.

Cemiplimab (Libtayo) was developed by Regeneron Pharmaceuticals and first approved by the FDA in 2018 for the treatment of cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation.

Experimental

As of 2017, at least five PD-1 inhibitors were under development.[7]

  • Spartalizumab (PDR001) is a PD-1 inhibitor, developed by Novartis to treat both solid tumors and lymphomas, which as of 2018 has entered Phase III trials.[12][13][14]
  • Camrelizumab (SHR1210) is an anti-PD-1 monoclonal antibody introduced by Jiangsu HengRui Medicine Co., Ltd. that recently received conditional approval in China for the treatment of relapsed or refractory classical Hodgkin lymphoma.[15]
  • Sintilimab (IBI308), a human anti-PD-1 antibody developed by Innovent and Eli Lilly, showing promising effect on non-small cell lung cancer (NSCLC) patients[16]
  • Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody in pivotal Phase 3 and Phase 2 clinical trials in solid tumors and hematologic cancers[17]
  • Toripalimab (JS 001) is a humanized IgG4 monoclonal antibody against PD-1 under clinical investigation [18]
  • Nivolumab (BMS-936558), developed by Bristol-Myers Squibb, is a fully human IgG4 inhibitor, currently evaluated on advanced or metastatic squamous Cell non-small cell lung cancer [19]
  • AMP-224, by GlaxoSmithKline
  • AMP-514, by GlaxoSmithKline

PD-L1

Atezolizumab (Tecentriq) is a fully humanised IgG1 (immunoglobulin 1) antibody developed by Roche Genentech. In 2016, the FDA approved atezolizumab for urothelial carcinoma and non-small cell lung cancer.

Avelumab (Bavencio) is a fully human IgG1 antibody developed by Merck Serono and Pfizer. Avelumab is FDA approved for the treatment of metastatic merkel-cell carcinoma. It failed phase III clinical trials for gastric cancer.[20]

Durvalumab (Imfinzi) is a fully human IgG1 antibody developed by AstraZeneca. Durvalumab is FDA approved for the treatment of urothelial carcinoma and unresectable non-small cell lung cancer after chemoradiation.[21]

Experimental

At least two PD-L1 inhibitors are in the experimental phase of development.

  • KN035 is the only PD-L1 antibody with subcutaneous formulation currently under clinical evaluations in the US, China, and Japan[22]
  • CK-301, by Checkpoint Therapeutics[23]
  • AUNP12 is a 29-mer peptide as the first peptic PD-1/PD-L1 inhibitor developed by Aurigene and Laboratoires Pierre Fabre that is being evaluated in clinical trial, following promising in vitro results.[24]
  • CA-170, discovered by Aurigene/Curis as the PD-L1 and VISTA antagonist, was indicted as a potent small molecule inhibitor in vitro. Thus, the compound is currently under phase I clinical trial over mesothelioma patients.[25]
  • BMS-986189, is a macrocyclic peptide discovered by Bristol-Myers Squibb of which the pharmacokinetics, safety and tolerability is currently being studied on healthy subjects.[26]

Adverse effects

Immunotherapies as a group have off-target effects and toxicities common to them. Some of these include interstitial pneumonitis, colitis, skin reactions, low levels of platelets and white blood cells, inflammation of the brain or spinal cord, neuromuscular adverse events[27] including myositis, Guillain-Barré syndrome, myasthenia gravis; myocarditis and cardiac insufficiency, acute adrenal insufficiency, and nephritis.[7] The detailed mechanism of these adverse effects are not fully elucidated[28]

When compared with standard chemotherapeutic agents, PD-1/PD-L1 inhibitors had a lower reported incidence of fatigue, sensory neuropathy, diarrhea, bone marrow suppression, loss of appetite, nausea, and constipation.[8]

See also

References

  1. ^ Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (23 August 2017). "PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome". Frontiers in Pharmacology. 8: 561. doi:10.3389/fphar.2017.00561. PMC 5572324. PMID 28878676.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ^ Francisco LM, Sage PT, Sharpe AH (July 2010). "The PD-1 pathway in tolerance and autoimmunity". Immunological Reviews. 236: 219–42. doi:10.1111/j.1600-065X.2010.00923.x. PMC 2919275. PMID 20636820.
  3. ^ Zhang YH, Tian M, Tang MX, Liu ZZ, Liao AH (September 2015). "Recent Insight into the Role of the PD-1/PD-L1 Pathway in Feto-Maternal Tolerance and Pregnancy". American Journal of Reproductive Immunology. 74 (3): 201–8. doi:10.1111/aji.12365. PMID 25640631.
  4. ^ Tanaka K, Albin MJ, Yuan X, Yamaura K, Habicht A, Murayama T, et al. (October 2007). "PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection". Journal of Immunology. 179 (8): 5204–10. doi:10.4049/jimmunol.179.8.5204. PMC 2291549. PMID 17911605.
  5. ^ a b c d Sunshine J, Taube JM (August 2015). "PD-1/PD-L1 inhibitors". Current Opinion in Pharmacology. 23: 32–8. doi:10.1016/j.coph.2015.05.011. PMC 4516625. PMID 26047524.
  6. ^ "The Science of PD-1 and Immunotherapy". Dana-Farber Cancer Institute. 13 May 2015.
  7. ^ a b c d e Iwai Y, Hamanishi J, Chamoto K, Honjo T (April 2017). "Cancer immunotherapies targeting the PD-1 signaling pathway". Journal of Biomedical Science. 24 (1): 26. doi:10.1186/s12929-017-0329-9. PMC 5381059. PMID 28376884.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  8. ^ a b c Gong J, Chehrazi-Raffle A, Reddi S, Salgia R (January 2018). "Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations". Journal for Immunotherapy of Cancer. 6 (1): 8. doi:10.1186/s40425-018-0316-z. PMC 5778665. PMID 29357948.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  9. ^ a b c Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731–e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
  10. ^ Guha M (2014). "Immune checkpoint inhibitors bring new hope to cancer patients". The Pharmaceutical Journal. {{cite journal}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  11. ^ Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. (April 2015). "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer". Science. 348 (6230): 124–8. doi:10.1126/science.aaa1348. PMC 4993154. PMID 25765070.
  12. ^ Kopp-Kubel S (1978-04-01). "International Nonproprietary Names (INN) for pharmaceutical substances". Bulletin of the World Health Organization. 73 (3): 275–9. doi:10.1093/ajhp/35.4.477a. PMC 2486664. PMID 7614659.
  13. ^ "PDR001". Immuno-Oncology News. Retrieved 2019-08-24.
  14. ^ "NCI Drug Dictionary". National Cancer Institute. 2011-02-02. Retrieved 2019-08-24.
  15. ^ Markham A, Keam SJ (August 2019). "Camrelizumab: First Global Approval". Drugs. 79 (12): 1355–1361. doi:10.1007/s40265-019-01167-0. PMID 31313098.
  16. ^ "Sintilimab - Eli Lilly/Innovent Biologics - AdisInsight". adisinsight.springer.com. Retrieved 2019-08-25.
  17. ^ "Library Association-Annual Meeting". The Library. s1-1 (1): 215. 1889-01-01. doi:10.1093/library/s1-1.1.215-b. ISSN 0024-2160.
  18. ^ "Toripalimab - Shanghai Junshi Biosciences - AdisInsight". adisinsight.springer.com. Retrieved 2019-08-25.
  19. ^ "Study of Nivolumab (BMS-936558) in Patients With Advanced or Metastatic Squamous Cell Nonsmall-cell Lung Cancer Who Have Received At Least 2 Prior Systemic Regimens - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-08-25.
  20. ^ Broderick, Jason M. (28 November 2017). "Avelumab Falls Short in Phase III Gastric Cancer Trial". OncLive. {{cite web}}: Unknown parameter |name-list-format= ignored (|name-list-style= suggested) (help)
  21. ^ AstraZeneca press release, 19 February 2018
  22. ^ Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, et al. (December 2017). "Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade". Cell Discovery. 3 (1): 17004. doi:10.1038/celldisc.2017.4. PMC 5341541. PMID 28280600.
  23. ^ Checkpoint Therapeutics press release, 21 March 2018
  24. ^ Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. (April 2017). "PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity". The Journal of Experimental Medicine. 214 (4): 895–904. doi:10.1084/jem.20160801. PMC 5379970. PMID 28302645.
  25. ^ Okazaki T, Honjo T (April 2006). "The PD-1-PD-L pathway in immunological tolerance". Trends in Immunology. 27 (4): 195–201. doi:10.1016/j.it.2006.02.001. PMID 16500147.
  26. ^ "Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of BMS-986189 in Healthy Subjects - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2019-08-24.
  27. ^ Johansen A, Christensen SJ, Scheie D, Højgaard JL, Kondziella D (April 2019). "Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review". Neurology. 92 (14): 663–674. doi:10.1212/WNL.0000000000007235. PMID 30850443.
  28. ^ Postow MA, Sidlow R, Hellmann MD (January 2018). "Immune-Related Adverse Events Associated with Immune Checkpoint Blockade". The New England Journal of Medicine. 378 (2): 158–168. doi:10.1056/NEJMra1703481. PMID 29320654.
Retrieved from "https://en.wikipedia.org/w/index.php?title=PD-1_and_PD-L1_inhibitors&oldid=918413447"